Phenytoin as a last‐resort treatment in SCN8A encephalopathy
Open Access
- 16 May 2017
- journal article
- research article
- Published by Wiley in Epilepsia Open
- Vol. 2 (3) , 343-344
Abstract
Summary: SCN8A encodes Nav1.6, one of the main voltage‐gated sodium channel subunits in the brain, and SCN8A mutations lead to epileptic encephalopathy. Particular mutations render the mutant channel more susceptible to inhibition by phenytoin. Yet, the potentially severe side effects of phenytoin maintenance therapy, especially cognitive impairment, are undesirable in these already cognitively impaired patients. We describe a 5‐year‐old patient with SCN8A encephalopathy in whom phenytoin proved successful as emergency treatment to prevent clustering of seizures and status epilepticus, thus hospital stays. The ketogenic diet, levetiracetam, zonisamide, topiramate, and phenytoin maintenance therapy resulted in adverse reactions not previously documented in SCN8A encephalopathy.Keywords
This publication has 8 references indexed in Scilit:
- The SCN8A encephalopathy mutation p.Ile1327Val displays elevated sensitivity to the anticonvulsant phenytoinEpilepsia, 2016
- SCN8A encephalopathy: Research progress and prospectsEpilepsia, 2016
- Remarkable Phenytoin Sensitivity in 4 Children with SCN8A-related Epilepsy: A Molecular Neuropharmacological ApproachNeurotherapeutics, 2015
- The phenotypic spectrum of SCN8A encephalopathyNeurology, 2015
- Characterization of a de novo SCN8A mutation in a patient with epileptic encephalopathyEpilepsy Research, 2014
- A Post-Hoc Comparison of the Utility of Sanger Sequencing and Exome Sequencing for the Diagnosis of Heterogeneous DiseasesHuman Mutation, 2013
- Sodium channels and the neurobiology of epilepsyEpilepsia, 2012
- Debate: Does genetic information in humans help us treat patients?Epilepsia, 2008